Thirty years of experience with recombinant human insulin-from familiarity to reliance / 中国糖尿病杂志
Chinese Journal of Diabetes
; (12): 84-88, 2018.
Article
en Zh
| WPRIM
| ID: wpr-703388
Biblioteca responsable:
WPRO
ABSTRACT
Recombinant human insulin,a milestone of diabetes treatment,has been put into clinical practice for over 30 years since 1980s.Its efficacy,safety and cost-effectiveness have been confirmed by clinical practice and clinical studies.Based on evidences,recombinant human insulin,among many antidiabetic agents,still remains one of the core hypoglycemic drugs recommended by authoritative guidelines for the prevention and treatment of diabetes.This review summarized the development,clinical efficacy,safety profiles and guideline recommendations of recombinant human insulin to lay the cornerstone of individualized insulin therapy.
Texto completo:
1
Índice:
WPRIM
Tipo de estudio:
Guideline
Idioma:
Zh
Revista:
Chinese Journal of Diabetes
Año:
2018
Tipo del documento:
Article